MedTrace Logo

Role of an E-cigarette on Smoking Displacement in Smokers With Schizophrenia

NCT03075202 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2019-01-11

No results posted yet for this study

Summary

It is well established in the scientific literature that people with schizophrenia smoke tobacco cigarettes at rates up to three times that of the general population, relapse more frequently, and die an average of 25 years earlier from cigarette smoking and other life-style attributable illnesses. Electronic cigarettes (e-cigarettes) are becoming increasingly popular with smokers worldwide and new research suggests that e-cigarettes are appealing to smokers with schizophrenia. There is a paucity of research focused on the experience of smokers with schizophrenia who decide to try an e-cigarette. A well-designed prospective-observational study is needed to learn more about the influence of e-cigarette use on cigarette smoking behavior and mental and physical health among smokers with schizophrenia. In response, the investigators have designed a study titled, Role of an electronic cigarette on smoking displacement in smokers with schizophrenia: A prospective 3-month pilot study (SchizEcig).

Conditions

  • Schizophrenia and Related Disorders

Interventions

DEVICE

e-cigarette, brand name JUUL

This is not an experimental study/trial, rather a prospective observational study. Device will be offered to cohort, but they are not mandated to take or use the device.

Sponsors & Collaborators

  • Hunter College of The City University of New York

    collaborator OTHER

  • University of Catania

    collaborator OTHER

  • University of Stirling

    collaborator OTHER

  • Weill Medical College of Cornell University

    lead OTHER

Principal Investigators

  • Jennifer DiPiazza-Sileo, PhD, PMHNP · Hunter College at The City University of New York

  • Caponnetto Pasquale, PhD · University of Catania

  • Jason J Kim, MD · Weill Medical College of Cornell University

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-03
Primary Completion
2018-12-24
Completion
2018-12-24

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03075202 on ClinicalTrials.gov